Using MRI to assess myelofibrosis
Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment
This study is testing if special MRI scans can help doctors see how severe myelofibrosis is and how well treatments are working for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 192 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Trial ID | NCT01973881 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing and validating functional MRI parameters as biomarkers to analyze the extent of myelofibrosis and quantify treatment responses. Researchers will utilize diffusion MRI and T1-weighted imaging to evaluate water and fat content in bone marrow, aiming to identify changes that predict therapy effectiveness. The goal is to establish MRI techniques that can provide earlier insights into disease severity and treatment response compared to current clinical measures. This foundational research may pave the way for larger trials assessing existing and new therapies for myelofibrosis.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 diagnosed with primary myelofibrosis or its post-polycythemia vera and post-essential thrombocythemia forms.
Not a fit: Patients with contraindications to MRI, such as those with pacemakers or other magnetic devices, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable earlier detection of treatment responses in myelofibrosis patients, leading to more timely and effective management of the disease.
How similar studies have performed: While this approach is innovative, similar studies using advanced MRI techniques have shown promise in other conditions, suggesting potential for success in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male /female subjects over the age of 18 2. Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. 3. No contraindications to MRI 4. Able to undergo MRI without anesthesia \- Exclusion Criteria: 1. Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner. 2. Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines. \-
Where this trial is running
Ann Arbor, Michigan
- University of Michigan Hospital — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Gary Luker, M.D. — University of Michigan Hospital
- Study coordinator: Gary Luker, M.D.
- Email: gluker@umich.edu
- Phone: 734-763-5476
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.